Predictive modeling helps target adherence outreach programming

Predictive modeling guides interventions for Star success

April 21, 2020

Adherence intervention using predictive modeling can deliver success large enough to affect Medicare Star ratings

This study paired Prime’s predictive modeling with its Medicare pharmacist call program to impact adherence to drugs for chronic conditions.

The study focused on drugs included in Star rating categories (oral diabetes) high cholesterol (statins) and high blood pressure (RAS). Star ratings are used by the Center for Medicare and Medicaid Services (CMS) to measure the quality of health plans.

The predictive model identified and ranked members likely to become nonadherent. Then Prime targeted those members with proactive pharmacist calls for adherence support. Members that received calls were followed and then assessed against a control group of members that did not receive calls.

The pharmacist calls improved members’ adherence in each category. This outreach to members, informed by Prime’s predictive model, was associated with significantly improved adherence and a Star Ratings increase of 0.9 – 1.1 percentage points. A single percentage point increase can bump a 3 to 4, or a 4 to 5 Star Rating.

A high Star Rating attracts people to a plan during open enrollment. In addition, health plans with a 4- or 5-Star Rating are eligible to receive significant performance bonuses. This can equate to hundreds of millions of dollars that health plans can use to improve benefits and/or reduce costs for their members.

AMCP recognized Prime’s research with a gold award. Prime is increasingly using predictive modeling to develop more effective and targeted clinical programming.

Proactive Pharmacist Call Program: Assessing the Impact of a Predictive Model-Driven Medicare Member Outreach on Adherence and Star Ratings (Fall 2019)

Related news

Perspectives

July 25, 2024

Quarterly Drug Pipeline: July 2024

Clinical insights and competitive intelligence on anticipated drugs in development

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Perspectives

July 22, 2024

Oncology Insights: 2024 ASCO Annual Meeting key findings

Findings from this year’s American Society of Clinical Oncology (ASCO) Annual Meeting will likely lead to clinical practice changes and U.S. Food and Drug Administration (FDA) drug approvals or expansions